AMENDMENTS

In the title

Please delete "MONOCLONAL".

In the specification

Page 1, lines 12-14, delete "(attorney docket number 30414-20003.00)" and "(attorney docket number 30414-20003.20)".

Page 14, line 8, delete "12301 Parklawn Drive, Rockville, MD, U.S.A. 20852", and substitute therefor --10801 University Boulevard, Manassas, VA, U.S.A. 20110-2209";

lines 13-14, delete "attorney docket number 30414-20003.00".

Page 78, lines 8-9, delete "attorney docket number 30414-20003.00".

In the claims

Please cancel claim 25.

Claim 1, line 2, insert --HB-- between "No." and "12020".

3. (Amended) A hybridoma cell line designated ATCC No. HB 12020 or [and] progeny thereof.

4. (Amended) A purified antibody having all the identifying characteristics of [identical to] antibody produced by a hybridoma cell line according to claim 3.

20. (Amended) A polypeptide having immunological activity of [monoclonal] anti-idiotype antibody 11D10, wherein the polypeptide comprises at least one complementarity determining region (CDR) from the light or heavy chain [5 contiguous amino acids from a] variable region of 11D10, wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained

B2 in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

B3 23. (Amended) The polypeptide of claim 20, wherein the light chain variable region [5 contiguous] amino acid[s] sequence is [are] contained in [depicted within] SEQ ID NO:2.

24. (Amended) The polypeptide of claim 20, wherein the heavy chain variable region [5 contiguous] amino acid[s] sequence is [are] contained in [depicted within] SEQ ID NO:4.

B4 37. (Amended) A [pharmaceutical] composition comprising [an effective amount of monoclonal] anti-idiotype antibody 11D10 of claim 1 and a pharmaceutically acceptable excipient.

Sub E6 39. (Amended) A [pharmaceutical] composition comprising [an effective amount of] the polypeptide of claim 20 and a pharmaceutically acceptable excipient.

B5 40. (Amended) An immunogenic composition [vaccine] comprising [an effective amount of monoclonal] anti-idiotype antibody 11D10 of claim 1 and a pharmaceutically acceptable excipient.

B6 42. (Amended) An immunogenic composition [vaccine] comprising [an effective amount of] the polypeptide of claim 20 and a pharmaceutically acceptable excipient.

B7 54. (Amended) A kit [for the detection or quantitation of an anti-human milk fat globule antibody] comprising [monoclonal] anti-idiotype antibody 11D10 of claim 1 in suitable packaging.

B8 56. (Amended) A kit [for the detection or quantitation of an anti-human milk fat globule antibody in a biological sample] comprising the 11D10 polypeptide of claim 20 in suitable packaging.